CN111455054B - Molecule for diagnosis and treatment of radioactive cancer - Google Patents
Molecule for diagnosis and treatment of radioactive cancer Download PDFInfo
- Publication number
- CN111455054B CN111455054B CN202010332154.6A CN202010332154A CN111455054B CN 111455054 B CN111455054 B CN 111455054B CN 202010332154 A CN202010332154 A CN 202010332154A CN 111455054 B CN111455054 B CN 111455054B
- Authority
- CN
- China
- Prior art keywords
- breast cancer
- expression level
- detecting
- reagent
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract description 24
- 201000011510 cancer Diseases 0.000 title abstract description 14
- 230000002285 radioactive effect Effects 0.000 title abstract description 9
- 238000003745 diagnosis Methods 0.000 title description 8
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 46
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 46
- 230000014509 gene expression Effects 0.000 claims abstract description 37
- 108020004459 Small interfering RNA Proteins 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 21
- 102000039446 nucleic acids Human genes 0.000 claims description 18
- 108020004707 nucleic acids Proteins 0.000 claims description 18
- 150000007523 nucleic acids Chemical class 0.000 claims description 18
- 239000003153 chemical reaction reagent Substances 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 101150090724 3 gene Proteins 0.000 claims description 10
- 239000000523 sample Substances 0.000 claims description 10
- 239000003112 inhibitor Substances 0.000 claims description 9
- 238000011529 RT qPCR Methods 0.000 claims description 8
- 230000003321 amplification Effects 0.000 claims description 8
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 7
- 238000005516 engineering process Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000003757 reverse transcription PCR Methods 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 4
- 238000007901 in situ hybridization Methods 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 239000002751 oligonucleotide probe Substances 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims 1
- 238000002474 experimental method Methods 0.000 abstract description 8
- 230000035755 proliferation Effects 0.000 abstract description 5
- 230000001105 regulatory effect Effects 0.000 abstract description 5
- 230000002452 interceptive effect Effects 0.000 abstract description 4
- 230000009545 invasion Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 2
- 239000004055 small Interfering RNA Substances 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 12
- 239000000203 mixture Substances 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 108010082117 matrigel Proteins 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 108091027967 Small hairpin RNA Proteins 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 239000003292 glue Substances 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 230000003827 upregulation Effects 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 108091027963 non-coding RNA Proteins 0.000 description 4
- 102000042567 non-coding RNA Human genes 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000713666 Lentivirus Species 0.000 description 3
- 108091081021 Sense strand Proteins 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000012165 high-throughput sequencing Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 102000014450 RNA Polymerase III Human genes 0.000 description 2
- 108010078067 RNA Polymerase III Proteins 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004709 cell invasion Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005865 ionizing radiation Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000001124 posttranscriptional effect Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- 208000019095 Radiation-induced disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 108091046869 Telomeric non-coding RNA Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000002247 constant time method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012067 mathematical method Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- LZFIOSVZIQOVFW-UHFFFAOYSA-N propyl 2-hydroxybenzoate Chemical class CCCOC(=O)C1=CC=CC=C1O LZFIOSVZIQOVFW-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a molecule for diagnosing and treating radioactive cancer, which is AP000251.3, and experiments prove that AP000251.3 is up-regulated in breast cancer, and the molecule can effectively distinguish the breast cancer from a normal population. The invention also proves that the proliferation activity and the invasion capacity of cancer cells can be reduced by interfering the expression of AP000251.3, and further, the breast cancer can be treated.
Description
Technical Field
The invention belongs to the field of biomedicine, and relates to a molecule for diagnosing and treating radioactive cancer.
Background
With the application of ionizing radiation in medical diagnosis and treatment, various medical large-scale radiation devices and application techniques thereof are being developed, and thus radiation injuries are increasing. Cancer induced by ionizing radiation is called radioactive cancer or radioactive tumor. Radioactive cancers are clinically and pathologically indistinguishable from cancers induced by other factors. Therefore, the early diagnosis of cancer is of great significance for the early treatment of diseases with different etiologies such as radiation-induced diseases.
Breast cancer is one of the most common cancers in women and is also one of the leading causes of female deaths from cancer, and has become a global public health problem. With the popularization of early disease discovery and the comprehensive treatment of surgical treatment, radiotherapy, chemotherapy, endocrine treatment and molecular targeted drugs, the death rate of breast cancer seems to be reduced, but the recurrence of breast cancer seems to be inevitable, so that the research on the occurrence and development processes of breast cancer is of great significance.
With the development of sequencing technology, it was found that about 98% of "garbage" DNA is transcribed into non-coding RNAs (ncRNAs) (Nie L, Wu HJ, Hsu JM, et al. Long non-coding RNAs: very large master regulators of gene expression and recombinant plasmids in cancer [ J ]. Am J Transl Res 2012,4(2): 127-) 150.) an important member of the non-coding RNA family is long-chain non-coding RNAs (lncRNA) whose transcript length exceeds 200 nucleotides and which do not code for proteins. The genome can be divided into five groups according to the genome position, namely sense lncRNA, antisense lncRNA, bidirectional lncRNA, intron lncRNA and intergenic lncRNA. In recent years more and more scholars have found that lncRNA plays an important role in many biological processes. Gene regulation of lncRNA can function at different levels, including chromatin modification, transcription, post-transcriptional processing, mRNA scaffolding or induction, and post-transcriptional messenger RNA regulation. Despite relatively few research efforts on lncRNA, the clinical application of lncRNA is an emerging hot field with broad prospects as a diagnostic marker and therapeutic target (Leucci E. cancer definition and therapy resistance: spotlights on the dark side of the genome [ J ]. Pharmacol Ther,2018,189: 22-30.). Therefore, the research on the correlation between the lncRNA and the breast cancer has important significance for the diagnosis and treatment of the breast cancer.
Disclosure of Invention
In order to make up for the defects of the prior art, the invention aims to provide a diagnosis and treatment marker related to radioactive cancer-breast cancer, which can be applied to clinic to realize early diagnosis and personalized treatment of breast cancer and improve the life quality of patients.
In order to achieve the purpose, the invention adopts the following technical scheme:
the invention provides application of a reagent for detecting AP000251.3 in preparation of a product for diagnosing early breast cancer.
Further, the reagent comprises a reagent for detecting the expression level of the AP000251.3 by reverse transcription PCR, real-time quantitative PCR, in-situ hybridization and a chip technology.
Further, the reagent for detecting the expression level of AP000251.3 by reverse transcription PCR at least comprises a pair of primers for specifically amplifying AP000251.3, the reagent for detecting the expression level of AP000251.3 by real-time quantitative PCR at least comprises a pair of primers for specifically amplifying AP000251.3, the reagent for detecting the expression level of AP000251.3 by in situ hybridization at least comprises a probe for specifically recognizing AP000251.3, and the reagent for detecting the expression level of AP000251.3 by chip technology at least comprises a probe for specifically recognizing AP 000251.3.
Further, the primer sequence of the specific amplification AP000251.3 for detecting the expression level of AP000251.3 by real-time quantitative PCR is shown in SEQ ID NO. 1-2.
The invention provides a product for diagnosing early breast cancer, which comprises a reagent for detecting the expression level of AP 000251.3.
Further, the product comprises a chip, a kit and a nucleic acid membrane strip.
Further, the chip comprises oligonucleotide probes specifically recognizing the AP 000251.3; the kit comprises a primer pair or a chip specific to the AP 000251.3; the nucleic acid membrane strip includes an oligonucleotide probe that specifically recognizes AP 000251.3.
Furthermore, the sequence of the primer pair specific to the AP000251.3 gene is shown in SEQ ID NO. 1-2.
The invention provides application of AP000251.3 in construction of a calculation model for predicting breast cancer.
The invention provides application of AP000251.3 in preparing a pharmaceutical composition for treating breast cancer.
Further, the pharmaceutical composition comprises an inhibitor of AP 000251.3.
Further, the inhibitor is selected from: nucleic acid molecules, carbohydrates, lipids, small molecule chemicals, or interfering lentiviruses.
Further, the inhibitor is a nucleic acid molecule.
Further, the nucleic acid molecule is siRNA.
Further, the sequence of the siRNA is shown in SEQ ID NO. 5-6.
The invention provides a pharmaceutical composition for treating breast cancer, which comprises an inhibitor of AP 000251.3.
Further, the inhibitor is selected from: nucleic acid molecules, carbohydrates, lipids, small molecule chemicals, or interfering lentiviruses.
Further, the inhibitor is a nucleic acid molecule.
Further, the nucleic acid molecule is siRNA.
Further, the sequence of the siRNA is shown in SEQ ID NO. 5-6.
The invention provides a method for screening a candidate drug for treating breast cancer, wherein if a substance to be screened reduces the expression level of AP000251.3, the substance to be screened is the candidate drug for treating the breast cancer.
The invention has the advantages and beneficial effects that:
the invention discovers that the differential expression of AP000251.3 is related to the occurrence and development of breast cancer for the first time, and whether a subject suffers from early breast cancer can be judged by detecting the expression level of AP000251.3, so that the early discovery and early treatment are realized, and the life quality of a patient is improved.
The invention also proves that AP000251.3 is related to proliferation and invasion of breast cancer cells through a functional verification experiment, thereby providing a new means for treating breast cancer.
Drawings
FIG. 1 is a graph showing the expression of AP000251.3 gene in a sample.
Fig. 2 is a graph of the effect of AP000251.3 on breast cancer cell invasion.
Detailed Description
The invention is widely and deeply researched, the transcription levels of lncRNA in a breast cancer sample and a normal sample are detected by a method of combining high-throughput sequencing with bioinformatics analysis, lncRNA fragments with obvious expression difference are found, and the relation between the lncRNA fragments and the occurrence of the breast cancer is discussed, so that a better way and a better method are found for the diagnosis and treatment of the breast cancer. Through screening, the invention discovers that AP000251.3 in a breast cancer patient is significantly up-regulated for the first time, and suggests that AP000251.3 can be used as a detection index for clinical diagnosis of breast cancer. Based on the up-regulation of the expression level of AP000251.3 in breast cancer patients, breast cancer is treated by designing a method of reducing the expression level of AP000251.3 by siRNA or the like.
AP000251.3 gene
The AP000251.3 gene is located on human chromosome 21, and the AP000251.3 of the present invention includes the AP000251.3 polynucleotide or a fragment, homolog, variant or derivative thereof. A representative nucleotide sequence of the AP000251.3 gene is shown in ENST 00000433071.2.
One skilled in the art will recognize that the utility of the present invention is not limited to quantifying gene expression of any particular variant of the target gene of the present invention. Two sequences are "substantially homologous" (or substantially similar) if, when the nucleic acid or fragment thereof is optimally aligned (with appropriate nucleotide insertions or deletions) with the other nucleic acid (or its complementary strand), there is nucleotide sequence identity in at least about 60% of the nucleotide bases, usually at least about 70%, more usually at least about 80%, preferably at least about 90%, and more preferably at least about 95-98% of the nucleotide bases.
The present invention may utilize any method known in the art for determining gene expression. It will be appreciated by those skilled in the art that the means by which gene expression is determined is not an important aspect of the present invention. The expression level of the biomarker can be detected at the transcriptional level. These techniques include, but are not limited to: nucleic acid sequencing techniques, nucleic acid hybridization techniques, and nucleic acid amplification techniques.
The present invention provides a computational model for predicting breast cancer, and as the skilled artisan will appreciate, the steps of correlating marker levels to a likelihood or risk can be carried out and carried out in different ways. Preferably, the measured concentrations of the marker and one or more other markers are mathematically combined and the combined value is correlated to the underlying diagnostic problem. The determination of marker values may be combined by any suitable prior art mathematical method.
Based on the findings of the present inventors, the present invention provides the use of AP000251.3 for the preparation of a pharmaceutical composition for the treatment of breast cancer, comprising an agent that specifically inhibits AP 000251.3. Such agents include, but are not limited to, nucleic acid molecules, carbohydrates, lipids, small molecule chemicals, or interfering lentiviruses.
In a preferred embodiment of the invention, the nucleic acid molecule includes, but is not limited to, an antisense oligonucleotide, double-stranded RNA (dsRNA), small interfering RNA (siRNA), or short hairpin RNA (shRNA).
Preferably, the small interfering RNA (sirna) comprises a first strand and a second strand, which are complementary to form an RNA dimer.
The small interfering RNA of the invention can be a chemically synthesized double-stranded RNA; it may also be a double-stranded RNA expressed by a vector or expression framework in which small interfering RNA expression in mammalian cells is regulated using, for example, an RNA polymerase III promoter including human or murine U6 promoter and human H1 promoter, and an RNA polymerase III terminator.
The small interfering RNA of the invention can be composed of a single small interfering RNA acting on a target sequence, or can be composed of a plurality of small interfering RNAs acting on a plurality of target sequences of a gene or target sequences on a plurality of genes; the target sequence can be the genome sequence of the AP000251.3 gene or the cDNA sequence of the AP000251.3 gene. Specifically, the small interfering RNA of the present invention may consist of at least one sequence in a sequence table.
Preferably, the short hairpin rna (shrna) comprises a sense strand segment and an antisense strand segment, and a stem-loop structure connecting the sense strand segment and the antisense strand segment, the sequences of the sense strand segment and the antisense strand segment being complementary. As an alternative embodiment, the sequence of the stem-loop structure of the shRNA may be selected from any one of the following sequences: UUCAAGAGA, AUG, CCC, UUCG, CCACC, CUCGAG, AAGCUU, and CCACACC.
In preparing the pharmaceutical compositions of the present invention, the active ingredient is typically mixed with, or diluted with, excipients or enclosed within a carrier which may be in the form of a capsule or sachet. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material that acts as a vehicle, carrier, or medium for the active ingredient. Thus, the composition may be in the form of tablets, pills, powders, solutions, syrups, sterile injectable solutions and the like. Examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starch, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, and the like. The formulation may further comprise: wetting agents, emulsifiers, preservatives (such as methyl and propyl hydroxybenzoates), sweeteners, and the like.
The application of the pharmaceutical composition provides a method for treating tumors, in particular to a method for preventing or treating tumors in a subject, which comprises the step of administering an effective dose of the pharmaceutical composition to the subject.
When the pharmaceutical composition is used for preventing or treating tumors in a subject, an effective dose of the pharmaceutical composition needs to be administered to the subject. Using this method, the growth, proliferation, recurrence and/or metastasis of the tumor is inhibited. Further, at least a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 99% fraction of the growth, proliferation, recurrence and/or metastasis of the tumor is inhibited.
The pharmaceutical compositions of the invention may also be used in combination with other agents for the treatment of breast cancer, and other therapeutic compounds may be administered simultaneously with the main active ingredient, even in the same composition.
The present invention is further illustrated below with reference to specific examples, which are provided only for the purpose of illustration and are not meant to limit the scope of the present invention.
The experimental procedures used in the following examples are all conventional procedures unless otherwise specified.
Materials, reagents and the like used in the following examples are commercially available unless otherwise specified.
Example 1 screening of Gene markers associated with early Breast cancer
1. Sample collection
31 samples of stage I-II breast cancer tissue and their corresponding paraneoplastic tissue samples (2 cm from the tumor margin) were collected, 4 of which were randomly selected for high throughput sequencing, all excluding other neoplastic diseases, autoimmune diseases and severe chronic diseases.
2. Preparation of RNA samples
The Trizol method is used for extracting RNA in tissues and comprises the following steps:
1) cutting tissue with scissors, adding 1ml Trizol, and shaking on oscillator for 1 min; standing at room temperature for 10 min.
2) Adding 200 μ l chloroform (chloroform), covering the tube, shaking vigorously for 15s, and standing at room temperature for 10 min.
3) Centrifuge at 11000rpm for 15min at 4 ℃.
4) Transferring the water sample layer into a new centrifuge tube, and adding 500 mul of isopropanol; after the mixture was inverted and mixed, the mixture was left standing at room temperature for 10 min.
5) Centrifuge at 11000rpm for 15min at 4 ℃.
6) The liquid was carefully aspirated off with a gun, the precipitate was left at the bottom of the tube, 1ml of 75% ethanol was added, the mixture was shaken on a shaker for 5s, and the precipitate was washed once.
7) Centrifuge at 8000rpm for 5min at 4 ℃.
8) Carefully removing the supernatant, drying the precipitate for 10min, and adding appropriate amount of water to dissolve the precipitate for 10 min.
3. Total RNA quantitation and purity analysis
The extracted RNA is subjected to agarose gel electrophoresis, the concentration and purity of the extracted RNA are detected by using Nanodrop2000, the integrity of the RNA is detected by the agarose gel electrophoresis, and the RIN value is determined by Agilent 2100. The total amount of RNA required for single library construction is 5 mug, the concentration is more than or equal to 200 ng/mug, and the OD260/280 is between 1.8 and 2.2.
4. Construction of cDNA library
1) Ribosomal RNA was removed from total RNA using the Ribo-Zero kit from Epicentre.
2) For the complete RNA sequence, metal ions are utilized to randomly break the RNA into small fragments of about 200 bp.
3) The construction of cDNA library was performed using Illumina Truseq RNA sample Prep Kit.
5. Sequencing
2X 150bp sequencing was performed using the Illumina X-Ten sequencing platform.
6. High throughput transcriptome sequencing data analysis
Deletion of non-detectable lncRNA differential expression analysis of reads numbers using DESeq2 in the R-3.3.3 tool, differential expression lncRNA screening criteria: FDR <0.05, abs (log2FC) > 2.
7. Results
High throughput sequencing results showed that AP000251.3 expression levels were significantly up-regulated in early breast cancer tissues compared to paracarcinoma tissues.
Example 2 QPCR sequencing verification of differential expression of AP000251.3 Gene
1. Large sample QPCR validation of AP000251.3 was performed using 31 previously collected tissue samples of early breast cancer and paracarcinoma tissue samples.
2. RNA extraction procedure as in example 1
3. qRT-PCR amplification assay
3.1 reverse transcription
The operation was carried out using a reverse transcription kit (Takara code: DRR047A) of TAKARA.
1) Removal of genomic DNA
Add 5 XgDNAeraser B. mu.ffer 2.0. mu.l, gDNA Eraser 1.0. mu.l, total RNA 1. mu.g, and RNase Free ddH into the tube2O to make the total volume to 10 μ l, heating in water bath at 42 deg.C for 2 min.
2) Reverse transcription reaction
5 XPrime
Buffer 2 4.0μl，Prime
RT Enzyme Mix I 1.0μl，RT Primer Mix 1.0μl，RNase Free ddH2O4.0. mu.l was added to the above test tube and mixed together to give 20. mu.l, which was then heated in a water bath at 37 ℃ for 15min and 85 ℃ for 5 s.
3.2 QPCR amplification
1) Primer design
Designing primers according to the gene sequences of AP000251.3 and GADPH, wherein the specific primer sequences are as follows:
AP000251.3(5’to 3’)：
ACGCTGTGGAAGATAAAC(SEQ ID NO.1)；
TGGGAGAGGGTTAAGAAG(SEQ ID NO.2)。
GAPDH(5’to 3’)：
AATCCCATCACCATCTTCCAG(SEQ ID NO.3)；
GAGCCCCAGCCTTCTCCAT(SEQ ID NO.4)。
2) QPCR amplification assay
By using
Premix Ex TaqTMII (Takara Code: DRR081) kit is configured with a PCR reaction system in a Thermal Cycler
PCR amplification is carried out on a Real Time System amplification instrument, after the reaction is finished, the amplification curve and the dissolution curve of the Real Time PCR are confirmed, and relative quantification is carried out by a delta CT method.
Prepare 25. mu.l reaction:
Reaction conditions are as follows: 30s at 95 ℃ (5 s at 95 ℃, 30s at 60 ℃) multiplied by 40
4. Results
The QPCR results are shown in fig. 1, compared with the paracancerous tissues, AP000251.3 was up-regulated in early breast cancer tissues, and the difference was statistically significant (P <0.05), wherein 28 cases of the samples showed significant up-regulation, 25 cases of the samples showed up-regulation in breast cancer tissues, 3 cases of the samples showed up-regulation in paracancerous tissues, and the expression up-regulation was regarded as positive (+), and no significant change or down-regulation was regarded as negative (-), and the specific statistics are shown in table 1, indicating that AP000251.3 as a molecular marker applied to the diagnosis of breast cancer has higher sensitivity and specificity, and can distinguish breast cancer from control population.
TABLE 1 expression of genes in samples
Example 3 functional verification of AP000251.3
1. Cell culture
BT474 cell line for breast cancer, cultured in DMEM medium containing 10% fetal bovine serum (Gibco) in 5% CO2And culturing at 37 deg.C in a constant temperature incubator.
2. Transfection
The general siRNA-NC and siRNA-AP000251.3 used in the application are purchased from Shanghai Ji code pharmaceutical technology GmbH, and the siRNA-AP000251.3 sequence for silencing AP000251.3 is shown as follows:
5’to 3’：
AGGUUAACAAAAAUGGAUGGG(SEQ ID NO.5)
CAUCCAUUUUUGUUAACCUCC(SEQ ID NO.6)
the experiments were divided into three groups, and the experiments were divided into 3 groups, namely a control group (BT474), a negative control group (siRNA-NC) and an experimental group (siRNA-AP 000251.3). Transfection was performed according to the instructions of the lipofectamine2000 transfection reagent from Invitrogen. The method comprises the following specific steps:
the day before the experiment, 6-well plates were plated with serum-free medium without double antibody, and the cell density was 6X 105A hole. Transfection was initiated when the degree of cell fusion reached 70%. 50. mu.L of OPTI-MEM was added to each 1.5ml of EP tube, and 5. mu.L of siRNA-AP000251.3, siRNA-NC and culture medium were added thereto, and the mixture was allowed to stand at room temperature for 5 min. Adding OPTI-MEM 30 μ L into each 1.5ml EP tube, adding Lipofectamine 20002 μ L, and standing at room temperature for 5 min; the diluted siRNA was gently mixed with Lipofectamine2000 and allowed to stand at room temperature for 20 min. Adding the mixed solution into each 6-pore plate containing the OPTI-MEM, and slightly and uniformly mixing the mixture front, back, left and right; after incubation in the incubator for 6h, the transfection solution was changed to a serum-free medium without double antibody.
3. Real-time PCR assay
After 48h of transfection and culture of each group of cells, total RNA of the cells was extracted by Trizol method, reverse transcription and real-time quantitative PCR detection were performed according to the method of example 2.
4. CCK-8 detection
Collecting cells in logarithmic growth phase, wherein the number of the cells added into each hole is 5000, each group is provided with 5 multiple holes and zero setting holes, the cells are placed at 37 ℃ and 5% CO2Culturing in an incubator, taking out cells after 48 hours, adding 10 mul of CCK-8 detection solution into each hole, continuously putting a 96-hole plate into the cell incubator to incubate for about 4 hours, detecting the absorbance value of each hole at the wavelength of 450nm by using an enzyme-labeling instrument, and recording data.
5. Transwell detection
Melting the Matrigel in an ice bath under aseptic condition, diluting the Matrigel glue according to the proportion of 1:8, slowly adding the Matrigel glue to the bottom of an upper chamber of a Transwell, spreading the Matrigel glue, and quickly transferring the Matrigel glue into a cell culture box at 37 ℃ for incubation until the Matrigel glue is solidified into a gel shape. The adding amount of the upper chamber is 1 multiplied by 105The lower chamber was filled with 600. mu.l of a medium containing 10% FBS, each set was set with 3 multiple wells, and cultured in a constant temperature incubator at 37 ℃ for 48 hours. Then, the Transwell was taken out and washed with PBS for 2 times, fixed with paraformaldehyde, stained with crystal violet, stained at room temperature for 20min, rinsed with PBS for 2 times, placed under a fluorescence microscope for observation and counted.
6. Statistical analysis
The experiments were performed in 3 replicates, and the results were expressed as mean ± sd, and the difference between the two was determined by paired t-test, which was considered statistically significant when P < 0.05.
7. Results
1) The expression level of AP000251.3 (0.227 ± 0.0862) in the experimental group after transfection of siRNA-AP000251.3 was significantly lower than that in the control group and the negative control group (BT474vs siRNA-AP000251.3, P value 0.0041,; siRNA-NC vs siRNA-AP000251.3 with P value of 0.0086, x), whereas the expression level of AP000251.3 in negative control transfected siRNA-NC was not significantly changed (BT474vs siRNA-NC with P value of 0.274, ns).
2) The CCK-8 assay results showed that the OD values (0.312 ± 0.065) of the experimental group were significantly reduced compared to the OD values (0.674 ± 0.0654) of the negative control group, and the differences were statistically significant (siRNA-NC vs siRNA-AP000251.3, P ═ 0.0003, x), indicating that the proliferation of BT474 cells was significantly inhibited after knock-down of AP 000251.3.
3) The cell invasion experiment result shows that the number of cells passing through the basement membrane is obviously reduced compared with that of a negative control group after AP000251.3 is knocked down (figure 2), the difference is statistically significant (siRNA-AP000251.3vs siRNA-NC, P ═ 0.0181), and the result shows that the invasion capacity of cancer cells BT474 in vitro can be inhibited after AP000251.3 is knocked down.
The above description of the embodiments is only intended to illustrate the method of the invention and its core idea. It should be noted that, for those skilled in the art, without departing from the principle of the present invention, several improvements and modifications can be made to the present invention, and these improvements and modifications will also fall into the protection scope of the claims of the present invention.
Sequence listing
<110> Qingdao city central hospital
<120> molecule for diagnosis and treatment of radioactive cancer
<160> 6
<170> SIPOSequenceListing 1.0
<210> 1
<211> 18
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
acgctgtgga agataaac 18
<210> 2
<211> 18
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
tgggagaggg ttaagaag 18
<210> 3
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
aatcccatca ccatcttcca g 21
<210> 4
<211> 19
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 4
gagccccagc cttctccat 19
<210> 5
<211> 21
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 5
agguuaacaa aaauggaugg g 21
<210> 6
<211> 21
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 6
cauccauuuu uguuaaccuc c 21
Claims (12)
1. Application of a reagent for detecting AP000251.3 in preparation of a product for diagnosing early breast cancer.
2. The use of claim 1, wherein the reagents comprise reagents for detecting the expression level of AP000251.3 by reverse transcription PCR, real-time quantitative PCR, in situ hybridization, chip technology.
3. The use according to claim 2, wherein the reagent for detecting the expression level of AP000251.3 by reverse transcription PCR comprises at least one pair of primers for specifically amplifying AP000251.3, the reagent for detecting the expression level of AP000251.3 by real-time quantitative PCR comprises at least one pair of primers for specifically amplifying AP000251.3, the reagent for detecting the expression level of AP000251.3 by in situ hybridization comprises a probe for specifically recognizing AP000251.3, and the reagent for detecting the expression level of AP000251.3 by chip technology comprises a probe for specifically recognizing AP 000251.3.
4. The use of claim 3, wherein the primer sequence of the specific amplification AP000251.3 for detecting the expression level of AP000251.3 by real-time quantitative PCR is shown as SEQ ID No. 1-2.
5. The use of claim 1, wherein the product comprises a chip, a kit, a nucleic acid membrane strip.
6. The use of claim 5, wherein the chip comprises oligonucleotide probes that specifically recognize AP 000251.3; the kit comprises a primer pair or a chip which is specifically aimed at the AP000251.3 gene; the nucleic acid membrane strip includes an oligonucleotide probe that specifically recognizes AP 000251.3.
7. The use according to claim 6, wherein the primer pair specific for the AP000251.3 gene has a sequence shown in SEQ ID No. 1-2.
Use of an inhibitor of AP000251.3 for the preparation of a pharmaceutical composition for the treatment of breast cancer, wherein said inhibitor reduces the expression level of AP 000251.3.
9. The use of claim 8, wherein the inhibitor is a nucleic acid molecule.
10. The use of claim 9, wherein the nucleic acid molecule is an siRNA.
11. The use of claim 10, wherein the siRNA has a sequence as shown in SEQ ID No. 5-6.
12. A method for screening a candidate drug for treating breast cancer, wherein if a substance to be screened decreases the expression level of AP000251.3, the substance to be screened is a candidate drug for treating breast cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010332154.6A CN111455054B (en) | 2020-04-24 | 2020-04-24 | Molecule for diagnosis and treatment of radioactive cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010332154.6A CN111455054B (en) | 2020-04-24 | 2020-04-24 | Molecule for diagnosis and treatment of radioactive cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111455054A CN111455054A (en) | 2020-07-28 |
| CN111455054B true CN111455054B (en) | 2021-03-16 |
Family
ID=71674631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010332154.6A Expired - Fee Related CN111455054B (en) | 2020-04-24 | 2020-04-24 | Molecule for diagnosis and treatment of radioactive cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111455054B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014159443A1 (en) * | 2013-03-14 | 2014-10-02 | Genomedx Biosciences, Inc. | Cancer biomarkers and classifiers and uses thereof |
-
2020
- 2020-04-24 CN CN202010332154.6A patent/CN111455054B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014159443A1 (en) * | 2013-03-14 | 2014-10-02 | Genomedx Biosciences, Inc. | Cancer biomarkers and classifiers and uses thereof |
Non-Patent Citations (3)
| Title |
|---|
| A RNA-Sequencing approach for the identification of novel long non-coding RNA biomarkers in colorectal cancer;Atsushi Yamada，等;《Scientific Reports》;20180112(第8期);第1-10页 * |
| Long Intergenic Non-Coding RNAs (LincRNAs) Identified by RNA-Seq in Breast Cancer;Xianfeng Ding，等;《PLOS ONE》;20140831;第9卷(第8期);第1-10页 * |
| Relationship of lncRNA to Breast Cancer;Alpizar-Reyes B，等;《Journal of Cancer Immunology》;20200407;第2卷(第1期);第22-34页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111455054A (en) | 2020-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2018129402A1 (en) | Compositions and methods used in diagnosing and treating colorectal cancer | |
| WO2011022316A1 (en) | Mirnas dysregulated in triple-negative breast cancer | |
| WO2009015071A1 (en) | Screening of micro-rna cluster inhibitor pools | |
| CN108753969B (en) | Application of long-chain non-coding RNA in hepatocellular carcinoma diagnosis and treatment | |
| US9421218B2 (en) | Compositions and methods for treatment of melanoma | |
| CN108220446B (en) | Application of LINC01356 as molecular marker in gastric cancer | |
| CN111187840A (en) | Biomarker for early breast cancer diagnosis | |
| CN111172290B (en) | MiRNA for diagnosis and treatment of hepatocellular carcinoma | |
| CN111778340B (en) | Biomarker for early cervical cancer diagnosis | |
| CN108660211B (en) | Hepatocellular carcinoma-related biomarker LINC01549 and application thereof | |
| CN111455054B (en) | Molecule for diagnosis and treatment of radioactive cancer | |
| CN111440874A (en) | Biomarker for diagnosing and treating oral squamous cell carcinoma | |
| CN110923324A (en) | Breast cancer miRNA marker and application thereof | |
| Joshi et al. | Noncoding RNA landscape and their emerging roles as biomarkers and therapeutic targets in meningioma | |
| EP2462951B1 (en) | Use of two microrna moleculars in lung cancer prognosis and medicine preparation | |
| CN108707672A (en) | Applications of the DUXAP8 in diagnosis of hepatoma and treatment | |
| CN111394464B (en) | Detection reagent for radioactive damage diseases and application thereof | |
| CN108165632B (en) | Application of LINC01426 in diagnosis and treatment of hepatocellular carcinoma | |
| CN109371136B (en) | Lung adenocarcinoma-related lncRNA and application thereof | |
| CN108624689B (en) | Application of biomarker LINC01451 | |
| CN111172289B (en) | Marker of miRNA for diagnosing and treating liver cancer | |
| CN111763735B (en) | Tumor differential expression gene and application thereof | |
| CN111440875A (en) | Biomarker-based diagnosis and use for treating cancer | |
| CN108841964B (en) | Application of LOC105370108 in diagnosis and treatment of rectal adenocarcinoma | |
| CN108950001B (en) | Molecular marker related to occurrence and development of rectal adenocarcinoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210316 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |